Company news

Racura Oncology Ltd news in 2026

Racura Oncology Ltd's news releases, calls and decks from 2026, newest first.

View company

Letter to Shareholders, Notice of AGM & Proxy Form

October 21, 2026

Sept 2026 Quarterly Activities Report and Appendix 4C

October 21, 2026

Sept 2026 Quarterly Activities Report and Appendix 4C

October 21, 2026

HARNESS-1 First Cohort Cleared

October 11, 2026

Racura Presents CPACS Data at GCOS 2026

October 6, 2026

Date of AGM & Closing Date for Director Nominations

October 4, 2026

Appendix 3Y - Dr Daniel Tillett

September 29, 2026

Appendix 3Y - Dr Daniel Tillett

September 22, 2026

RC220 MYC-silencing data to be presented FCS 26 conference

September 7, 2026

Racura Oncology Adelaide Investor Briefing

September 3, 2026

Notification regarding unquoted securities - RAC

August 31, 2026

CPACS Trial Opens for RC220 Patient Enrolment in Korea

August 31, 2026

Corporate Governance Statement

August 25, 2026

Appendix 4G

August 25, 2026

Appendix 4E & Annual Report

August 25, 2026

First HARNESS-1 Patient Safely Treated with RC220

July 28, 2026

Racure Oncology Techknow Invest Presentation

July 28, 2026

June 2026 Quarterly Activities Report and Appendix 4C

July 27, 2026

Bellberry Ethics Approval Activates New HARNESS Trial Sites

July 2, 2026

Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer

June 25, 2026

Racura Treats First Patient in HARNESS-1 Lung Cancer Trial

June 24, 2026

Racura raised $34.3m to Advance Three Oncology Trials

June 15, 2026

Emerging Companies Specialist Invests in Racura

June 3, 2026

Racura Enters Underwriting Agreement for Options

May 28, 2026

Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial

May 15, 2026

CPACS Trial Cleared to Escalate to Next RC220 Dose Level

May 14, 2026

(E,E)-bisantrene Discovered to Function via Silencing of c-MYC Expression

May 6, 2026

March 2026 Quarterly Activity Report and Appendix 4C

April 29, 2026

Racura presents MYC silencing data at AACR 2026

April 22, 2026

First Patient Recruited to HARNESS-1 Lung Cancer Trial

March 31, 2026

First Patient Dosed Safely with RC220 in Hong Kong

March 18, 2026

Racura HARNESS-1 Trial Receives Governance Approval

March 15, 2026

Appendix 4D & Half-Year Financial Statements

February 27, 2026

Racura Develops Novel Cardioprotection Blood Test

February 10, 2026

December 2025 Quarterly Activity Report and Appendix 4C

January 28, 2026

Racura Oncology Emory University Collaboration

January 13, 2026

Decks in 2026